A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs NX-5948 (Primary)
- Indications Autoimmune haemolytic anaemia; B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Nurix
- 28 Jan 2025 According to a Nurix media release, company is exploring the filing of a non-malignant hematology IND for autoimmune cytopenias in 2025.Future clinical updates in patients with both CLL and non-Hodgkins lymphoma are anticipated in 2025.
- 13 Jan 2025 According to a Nurix media release, the company plans to initiate clinical testing of NX-5948 in autoimmune cytopenias such as warm autoimmune hemolytic anemia (wAIHA) in 2025, initially as an addition to its ongoing Phase 1b trial in patients with B-cell malignancies.
- 24 Dec 2024 Planned number of patients changed from 292 to 492.